-
Dutch drug regulator reports 10 cases of possible thrombosis after AstraZeneca jab

The Netherlands has seen 10 cases of noteworthy adverse side effects from AstraZeneca’s COVID-19 vaccine, a Dutch drug watchdog said on Monday, hours after the government put its vaccination program on hold following reports of possible unexpected side effects in other countries.
The Pharmacovigilance Centre Lareb said in a statement that 10 cases of reported side effects seen with the vaccine in the Netherlands included cases of possible thrombosis or embolisms, but none of the cases also included a lowered number of platelets, as has been reported reported in Denmark and Norway.
The Dutch government announced shortly before midnight on Sunday that it was halting use of the AstraZeneca vaccine. Its decision came hours before the Dutch began casting votes in a national election seen as a referendum on the government’s handling of the coronavirus pandemic.
The decision meant 43,000 vaccination appointments would be cancelled at short notice, the country’s health authorities said.
European vaccination programs have been upset in the last two weeks by reports that recipients of the AstraZeneca inoculation have suffered blood clots.
The European Medicines Agency has said there is no indication that the events were caused by the vaccination, a view that was echoed by the World Health Organization on Friday.
The Dutch vaccination program got off to a slow start, but hoped to catch up using the Pfizer-BioNtech, Moderna vaccines,and later the Johnson & Johnson vaccine. AstraZeneca, however, was to have accounted for 30 percent of 4.3 million vaccinations through April 15.
The Dutch health ministry said it hoped to resume vaccinations with AstraZeneca within several weeks, describing the halt as a “pause” taken only as a precaution.
“I hope (the halt will last) no longer than a couple of weeks, because we need vaccines to be able to put this nasty period behind us,” Health Minister Hugo de Jonge said on an early morning talk show.
The move follows a report that health workers in Norway who had recently received the vaccine were being treated in hospital for bleeding, blood clots and a low count of blood platelets.
The Netherlands has pre-ordered 12 million doses of AstraZeneca’s vaccine.
AstraZeneca said on Sunday a review of safety data of people vaccinated with its COVID-19 vaccine had shown no evidence of an increased risk of blood clots.
Denmark, Norway, Ireland, Iceland and Thailand have halted use of AstraZeneca’s vaccine over blood clotting concerns.
Italy’s northern region of Piedmont on Sunday said it would stop using a batch of AstraZeneca vaccines after a teacher died following his vaccination on Saturday, while Austria also stopped using a particular batch last week.
source: Reuters
Image source: Reuters
Levant
You May Also Like
Popular Posts
Caricature
BENEFIT Sponsors BuildHer...
- April 23, 2025
BENEFIT, the Kingdom’s innovator and leading company in Fintech and electronic financial transactions service, has sponsored the BuildHer CityHack 2025 Hackathon, a two-day event spearheaded by the College of Engineering and Technology at the Royal University for Women (RUW).
Aimed at secondary school students, the event brought together a distinguished group of academic professionals and technology experts to mentor and inspire young participants.
More than 100 high school students from across the Kingdom of Bahrain took part in the hackathon, which featured an intensive programme of training workshops and hands-on sessions. These activities were tailored to enhance participants’ critical thinking, collaborative problem-solving, and team-building capabilities, while also encouraging the development of practical and sustainable solutions to contemporary challenges using modern technological tools.
BENEFIT’s Chief Executive Mr. Abdulwahed AlJanahi, commented: “Our support for this educational hackathon reflects our long-term strategic vision to nurture the talents of emerging national youth and empower the next generation of accomplished female leaders in technology. By fostering creativity and innovation, we aim to contribute meaningfully to Bahrain’s comprehensive development goals and align with the aspirations outlined in the Kingdom’s Vision 2030—an ambition in which BENEFIT plays a central role.”
Professor Riyadh Yousif Hamzah, President of the Royal University for Women, commented: “This initiative reflects our commitment to advancing women in STEM fields. We're cultivating a generation of creative, solution-driven female leaders who will drive national development. Our partnership with BENEFIT exemplifies the powerful synergy between academia and private sector in supporting educational innovation.”
Hanan Abdulla Hasan, Senior Manager, PR & Communication at BENEFIT, said: “We are honoured to collaborate with RUW in supporting this remarkable technology-focused event. It highlights our commitment to social responsibility, and our ongoing efforts to enhance the digital and innovation capabilities of young Bahraini women and foster their ability to harness technological tools in the service of a smarter, more sustainable future.”
For his part, Dr. Humam ElAgha, Acting Dean of the College of Engineering and Technology at the University, said: “BuildHer CityHack 2025 embodies our hands-on approach to education. By tackling real-world problems through creative thinking and sustainable solutions, we're preparing women to thrive in the knowledge economy – a cornerstone of the University's vision.”
opinion
Report
ads
Newsletter
Subscribe to our mailing list to get the new updates!